Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interleukin-1 receptor antagonist - Pharmacia

Drug Profile

Interleukin-1 receptor antagonist - Pharmacia

Alternative Names: Interleukin-1 receptor antagonist protein; IRAP; Recombinant human interleukin-1 receptor antagonist protein; Recombinant interleukin-1 receptor antagonist protein; rIRAP

Latest Information Update: 28 Feb 1996

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmacia Corporation
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Interleukin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Inflammation; Rheumatic disorders; Type 1 diabetes mellitus

Most Recent Events

  • 28 Feb 1996 The new ATC/EphMRA codes for interleukin-1 receptor antagonist are A10X/A10X.
  • 28 Feb 1996 No-Development-Reported for Rheumatic disorders in USA (Unknown route)
  • 28 Feb 1996 No-Development-Reported for Type-1 diabetes mellitus in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top